163 related articles for article (PubMed ID: 33360648)
1. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review.
Pathmanathan K; Robinson PC; Hill CL; Keen HI
Semin Arthritis Rheum; 2021 Feb; 51(1):121-128. PubMed ID: 33360648
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of the prevalence of gout and hyperuricaemia in Australia.
Robinson PC; Taylor WJ; Merriman TR
Intern Med J; 2012 Sep; 42(9):997-1007. PubMed ID: 24020339
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and associations of gout and hyperuricaemia: results from an Australian population-based study.
Ting K; Gill TK; Keen H; Tucker GR; Hill CL
Intern Med J; 2016 May; 46(5):566-73. PubMed ID: 26765205
[TBL] [Abstract][Full Text] [Related]
4. Gout and hyperuricaemia in the USA: prevalence and trends.
Singh G; Lingala B; Mithal A
Rheumatology (Oxford); 2019 Dec; 58(12):2177-2180. PubMed ID: 31168609
[TBL] [Abstract][Full Text] [Related]
5. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
6. Hyperuricaemia, gout and allopurinol in the CKD Queensland registry.
Jeyaruban A; Hoy W; Cameron A; Healy H; Wang Z; Zhang J; Mallett A
J Nephrol; 2021 Jun; 34(3):753-762. PubMed ID: 33439469
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology of gout and hyperuricaemia in Italy during the years 2005-2009: a nationwide population-based study.
Trifirò G; Morabito P; Cavagna L; Ferrajolo C; Pecchioli S; Simonetti M; Bianchini E; Medea G; Cricelli C; Caputi AP; Mazzaglia G
Ann Rheum Dis; 2013 May; 72(5):694-700. PubMed ID: 22736095
[TBL] [Abstract][Full Text] [Related]
8. Risk of dementia in gout and hyperuricaemia: a meta-analysis of cohort studies.
Pan SY; Cheng RJ; Xia ZJ; Zhang QP; Liu Y
BMJ Open; 2021 Jun; 11(6):e041680. PubMed ID: 34158290
[TBL] [Abstract][Full Text] [Related]
9. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease.
Borghi C; Agabiti-Rosei E; Johnson RJ; Kielstein JT; Lurbe E; Mancia G; Redon J; Stack AG; Tsioufis KP
Eur J Intern Med; 2020 Oct; 80():1-11. PubMed ID: 32739239
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.
Feher MD; Hepburn AL; Hogarth MB; Ball SG; Kaye SA
Rheumatology (Oxford); 2003 Feb; 42(2):321-5. PubMed ID: 12595630
[TBL] [Abstract][Full Text] [Related]
11. Hyperthyroid and hypothyroid status was strongly associated with gout and weakly associated with hyperuricaemia.
See LC; Kuo CF; Yu KH; Luo SF; Chou IJ; Ko YS; Chiou MJ; Liu JR
PLoS One; 2014; 9(12):e114579. PubMed ID: 25486420
[TBL] [Abstract][Full Text] [Related]
12. An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population.
Robinson PC; Taylor WJ; Dalbeth N
J Rheumatol; 2015 Sep; 42(9):1702-7. PubMed ID: 26233513
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal.
Stevenson M; Pandor A
Pharmacoeconomics; 2011 Feb; 29(2):133-40. PubMed ID: 21155617
[TBL] [Abstract][Full Text] [Related]
14. Allopurinol initiation and all-cause mortality in the general population.
Dubreuil M; Zhu Y; Zhang Y; Seeger JD; Lu N; Rho YH; Choi HK
Ann Rheum Dis; 2015 Jul; 74(7):1368-72. PubMed ID: 24665118
[TBL] [Abstract][Full Text] [Related]
15. The gout epidemic in French Polynesia: a modelling study of data from the Ma'i u'u epidemiological survey.
Pascart T; Wasik KA; Preda C; Chune V; Torterat J; Prud'homme N; Nassih M; Martin A; Le Masson J; Rodière V; Frogier S; Canova G; Pescheux JP; Shan Sei Fan C; Jauffret C; Claeys P; von Baeyer SL; Castel SE; Emde AK; Yerges-Armstrong L; Fox K; Leask M; Vitagliano JJ; Graf S; Norberciak L; Raynal J; Dalbeth N; Merriman T; Bardin T; Oehler E
Lancet Glob Health; 2024 Apr; 12(4):e685-e696. PubMed ID: 38485432
[TBL] [Abstract][Full Text] [Related]
16. Wastewater-based prevalence trends of gout in an Australian community over a period of 8 years.
Ahmed F; Tscharke B; O'Brien JW; Zheng Q; Thompson J; Mueller JF; Thomas KV
Sci Total Environ; 2021 Mar; 759():143460. PubMed ID: 33234275
[TBL] [Abstract][Full Text] [Related]
17. Is coffee consumption associated with a lower risk of hyperuricaemia or gout? A systematic review and meta-analysis.
Zhang Y; Yang T; Zeng C; Wei J; Li H; Xiong YL; Yang Y; Ding X; Lei G
BMJ Open; 2016 Jul; 6(7):e009809. PubMed ID: 27401353
[TBL] [Abstract][Full Text] [Related]
18. Suboptimal physician adherence to quality indicators for the management of gout and asymptomatic hyperuricaemia: results from the UK General Practice Research Database (GPRD).
Mikuls TR; Farrar JT; Bilker WB; Fernandes S; Saag KG
Rheumatology (Oxford); 2005 Aug; 44(8):1038-42. PubMed ID: 15870145
[TBL] [Abstract][Full Text] [Related]
19. Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study.
Pisaniello HL; Lester S; Gonzalez-Chica D; Stocks N; Longo M; Sharplin GR; Dal Grande E; Gill TK; Whittle SL; Hill CL
Arthritis Res Ther; 2018 Jul; 20(1):143. PubMed ID: 29996922
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
Stevenson M; Pandor A
Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
